Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment.
BACKGROUND
Botulinum Toxin Type-A (BoNT/A) intraprostatic injection can induce prostatic involution and improve LUTS and urinary flow in patients with Benign Prostatic Enlargement (BPE). However, the duration of these effects is unknown. The objective of this work was to determine the duration of prostate volume reduction after one single intraprostatic injection of 200U of Botulinum Toxin Type-A.


METHODS
This is an extension of a 6 month study in which 21 frail elderly patients with refractory urinary retention and unfit for surgery were submitted to intraprostatic injection of BoNT/A-200U, by ultrasound guided transrectal approach. In spite of frail conditions, eleven patients could be followed during 18 months. Prostate volume, total serum PSA, maximal flow rate (Qmax), residual volume (PVR) and IPSS-QoL scores were determined at 1, 3, 6, 12 and 18 months post-treatment.


RESULTS
Mean prostate volume at baseline, 82 +/- 16 ml progressively decreased from month one coming to 49 +/- 9,5 ml (p = 0,003) at month six. From this moment on, prostate volume slowly recovered, becoming identical to baseline at 18 months (73 +/- 16 ml, p = 0.03). Albeit non significant, serum PSA showed a 25% decrease from baseline to month 6. The 11 patients resumed spontaneous voiding at month one. Mean Qmax was 11,3 +/- 1,7 ml/sec and remained unchanged during the follow-up period. PVR ranged from 55 +/- 17 to 82 +/- 20 ml and IPSS score from10 to 12 points.


CONCLUSIONS
Intraprostatic BoNT/A injection is safe and can reduce prostate volume for a period of 18 months. During this time a marked symptomatic improvement can be maintained.
Silva
João
J
Department of Urology, Hospital S, João, Porto, Portugal. jfalturas@gmail.com
Pinto
Rui
R
Carvalho
Tiago
T
Botelho
Francisco
F
Silva
Pedro
P
Oliveira
Rui
R
Silva
Carlos
C
Cruz
Francisco
F
Dinis
Paulo
P
D000368:Aged; D000369:Aged, 80 and over; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000175:diagnosis* / Q000188:drug therapy*; D016896:Treatment Outcome
D019274:Botulinum Toxins, Type A
Urology. 2005 Oct;66(4):775-9
16230137
J Urol. 2008 Oct;180(4):1314-7; discussion 1317
18707733
Br J Pharmacol. 2006 Feb;147 Suppl 2:S88-119
16465187
Neurourol Urodyn. 2007 Oct;26(6 Suppl):920-7
17705161
BMC Urol. 2006 Apr 18;6:12
16620393
Urology. 2009 Jan;73(1):90-4
18995889
Toxicon. 2009 Oct;54(5):668-74
19470342
Prostate. 1998 Sep 15;37(1):44-50
9721068
Urology. 2005 Apr;65(4):670-4
15833506
Scand J Urol Nephrol. 2009;43(3):206-11
19308807
Eur Urol. 2008 Jan;53(1):153-9
17825981
Eur Urol. 2009 Jul;56(1):134-40
18649990
BJU Int. 2006 Nov;98(5):1033-7; discussion 1337
16956361
Yonsei Med J. 2006 Oct 31;47(5):706-14
17066515
Eur Urol. 2008 Aug;54(2):326-34
18160204
Eur Urol. 2007 Aug;52(2):582-9
17386969
Urology. 2003 Aug;62(2):259-64; discussion 264-5
12893330
Urology. 2001 Dec;58(6 Suppl 1):65-70; discussion 70
11750255
Eur Urol. 2008 Oct;54(4):765-75
18571306
Urology. 2001 Dec;58(6 Suppl 1):25-32; discussion 32
11750246